Deuterocactinib is an oral targeted therapy primarily used to treat moderate to severe plaque psoriasis and other immune-related diseases. Its price f···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 136
The current domestic price of deuterocelexitinib (14 tablets) is approximately 4300-4800 RMB per box (14 tablets). The specific price may fluctuate sl···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 113
Bristol-Myers Squibb (BMS) recently announced that the pivotal Phase 3 POETYK PSO-1 study evaluating the novel anti-inflammatory drug deucravacitinib ···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 137
On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 125
On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 124
Bristol-Myers Squibb announced on September 9, 2022, that the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the t···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 134
The European Commission (EC) recently approved Bristol-Myers Squibb's Sotyktu (deucravacitinib) as a once-daily oral tablet for the treatment of a···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 146
Bristol-Myers Squibb recently announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the treatment of act···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 110
Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 112
Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 113
On April 17, 2020, the U.S. Food and Drug Administration (FDA) approved the new breast cancer drug Tukysa in combination with trastuzumab (Herceptin) ···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 125
On July 2, 2022, Seagen announced the full results of the pivotal Phase 2 MOUNTAINEER trial, demonstrating that tucatinib (trademark: TUKYSA) in combi···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 120
The price of Eltrombopag varies depending on factors such as specifications, dosage form, and whether it is imported or domestically produced. It typi···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 110
The price of eltrombopag (generic name: eltrombopag ethanolamine tablets) varies depending on factors such as specifications, origin, and purchase cha···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 117
The price of eltrombopag varies depending on dosage, strength, purchase channel, and region, typically ranging from 2000 to 6000 yuan per box. For spe···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 123
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos



